Secukinumab 150mg
| Product Overview | |
| Generic Name | Secukinumab 150mg |
| Brand Name(s) | Cosentyx |
| Form | 150mg Vial, Prefilled injection pens |
| Strength | 150mg/mL |
| Therapeutic Class | Interleukin-17A inhibitor for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis |
| ATC Code | L04AC10 |
| Manufacturing & Regulatory | |
| Manufacturer | Novartis Europharm Limited |
| Country | Ireland, Dublin |
| GMP Compliance | WHO-GMP, EU-GMP |
| DMF/CEP | Not applicable (biologic) |
| COFEPRIS | 010.000.6080.00 |
| Free Sale Certificate | Yes. MAH can provide CPP/FSC for institutional channels |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | Refrigerated (2–8 °C) |
| Incoterms | EXW/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| SDS | Manufacturer provides standard SDS (biologic/aqueous injectable) |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
Secukinumab is a human IgG1κ anti-IL-17A mAb indicated for moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, enthesitis-related arthritis / juvenile PsA, and hidradenitis suppurativa
